The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -3.19 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.63 — no flag raisedOK
- Earnings quality 79/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Zymeworks Inc. reports it. History and quarterly detail are in the app.
- Commercial Sales Milestones$867.0M
- Commercial Milestones$170.0M
- Development Milestone$168.5M
- Research Milestone$35.0M
- Milestone revenue$25.0M
Leadership changes
From Zymeworks Inc.'s own filings, the day they're filed.
- Kristin Stafford · President · appointmenteff. 2026-03-31
- Oleg Nodelman · director · appointmenteff. 2025-02-17
- Hollings C. Renton · directors · departureeff. 2024-12-10
Latest filings
- 8-K · Company announcement2026-08-25
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Zymeworks Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Zymeworks Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.